VISEN Pharmaceuticals

02561

Company Profile

  • Business description

    VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.

  • Contact

    69 Jiuzhang Road
    Suite 3-108, Floor 3, Building B
    Hengtai Lixiang Chuangxin Tower
    Suzhou
    CHN

    http://www.visenpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    52

Stocks News & Analysis

stocks

Our three most overvalued ASX shares

These three companies are trading at a significant premium to our fair value.
stocks

What does big US court decision mean for Google’s parent company Alphabet?

Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.
stocks

Our only 5-star wide moat ASX share

A difficult year but better times ahead.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,126.902.50-0.03%
CAC 407,720.4421.520.28%
DAX 4023,702.04105.060.45%
Dow JONES (US)45,316.53304.76-0.67%
FTSE 1009,227.0418.830.20%
HKSE25,633.91215.930.85%
NASDAQ21,700.397.30-0.03%
Nikkei 22543,643.81625.061.45%
NZX 50 Index13,281.1457.610.44%
S&P 5006,464.5816.92-0.26%
S&P/ASX 2008,849.605.60-0.06%
SSE Composite Index3,826.8414.330.38%

Market Movers